Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New camera eye could catch colon cancer early in IBD patients

NCT ID NCT07271264

Diagnosis Sponsor: London North West Healthcare NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new imaging technique called Texture and Colour Enhancement Imaging (TXI) with standard white light during colonoscopy in 219 people with inflammatory bowel disease (IBD). The goal is to see if TXI finds more dysplastic (precancerous) lesions. Each patient will have both methods used in different parts of their colon, and the number of lesions detected will be compared.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Texture and Colour Enhancement Imaging (TXI) system
What this could lead to
If TXI proves better at detecting dysplasia, it could become a new standard for IBD surveillance, catching precancerous changes earlier.
What could go wrong
This is a relatively small, early-stage study. TXI may not outperform standard white light, and results may not apply to all IBD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 219 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \>16 with inflammatory bowel disease undergoing surveillance colonoscopy. * Patients with Crohn's (L2/L3 Montreal classification) with \>50% colonic involvement OR * Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD. Exclusion Criteria: * Disease duration \<8 years unless a diagnosis of PSC * Incomplete colonoscopy * BBPS \<6 or \<2 in any segment * MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for \>10cm segment (above the rectum) * Previous colorectal resection * Thrombocytopaenia (platelet count \<50) or Coagulopathy precluding biopsy * Anticoagulation that has not been held appropriately prior to the procedure (must be held at least the morning of the procedure). * Pregnancy * Unable or unwilling to consent to study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Central Middlesex Hospital

    RECRUITING

    London, NW10 7NS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.